This inventor holds 6 USPTO granted patents and 2 published patent applications. Top assignees: Academia Sinica, National Taiwan University. Active years: 2015-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2015-2024
Title: The Innovative Contributions of Rong-Jie Chein
Introduction
Rong-Jie Chein is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating various proliferative diseases, including cancers. With a total of six patents to his name, Chein's work is recognized for its potential impact on medical treatments.
Latest Patents
Chein's latest patents include innovative methods of using 4(1)-quinolone derivatives. These compounds are designed to treat, delay, and prevent the adverse effects of proliferative diseases such as lung cancer, breast cancer, and leukemia. The patents detail methods for inhibiting the polymerization of cancer cell microtubules, which can lead to apoptosis in drug-resistant cancer cells. Additionally, he has developed 4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives, which are useful in treating both proliferative and infectious diseases.
Career Highlights
Throughout his career, Chein has worked with esteemed institutions such as Academia Sinica and National Taiwan University. His research has focused on creating pharmaceutical compositions and methods that address critical health challenges, particularly in oncology.
Collaborations
Chein has collaborated with notable colleagues, including Pan-Chyr Yang and Ting-Jen Rachel Cheng. These partnerships have contributed to the advancement of his research and the development of innovative treatments.
Conclusion
Rong-Jie Chein's contributions to the field of pharmaceuticals through his patents and research collaborations highlight his role as a key innovator in the fight against cancer and other diseases. His work continues to pave the way for new therapeutic approaches that may significantly improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile